Research programme: DNA vaccines - Inovio

Drug Profile

Research programme: DNA vaccines - Inovio

Alternative Names: Chikungunya virus DNA vaccine - Inovio; CHIKV vaccine - Inovio; Cytomegalovirus DNA vaccine - Inovio; dMab HIV - Inovio; DNA vaccine against HIV clade C - Inovio; INO 4500; INO 5400; INO-5401; Malaria vaccine - Inovio; Smallpox vaccine - Inovio; SynCon WT1 cancer immunotherapy

Latest Information Update: 04 Apr 2016

Price : $50

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Drexel University College of Medicine; Inovio Pharmaceuticals
  • Class AIDS vaccines; Bacterial vaccines; Cancer vaccines; DNA vaccines; Hepatitis C vaccines; Parasitic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Smallpox

Highest Development Phases

  • Preclinical Cancer; Chikungunya virus infections; Clostridium infections; Cytomegalovirus infections; Hepatitis C; Human papillomavirus infections; Malaria; Malignant melanoma; Tuberculosis
  • Research Smallpox

Most Recent Events

  • 27 Feb 2017 Inovio plans a clinical trial for Cancer (Combination therapy)
  • 22 Mar 2016 Pharmacodynamics data from a preclinical trial in Chikungunya virus infections released by Inovio Pharmaceuticals
  • 20 Nov 2014 Preclinical trials in Malignant melanoma in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top